Compare KB Financial Group, Inc. (KB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Revvity Inc — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: KB Financial Group, Inc. is far larger — about 2.5× Revvity Inc's market cap, and KB Financial Group, Inc. pays the higher dividend (2.71%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Revvity Inc for 12 Days on average.
| KB | RVTY | |
|---|---|---|
Market Cap | $42.62B | $16.98B |
Volume | 164,291 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $132.88 | $157.36 |
52-Week Low | $77.50 | $82.26 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $215.53T | $19.30B |
Dividend Yield | 2.71% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $122.04, down 2.16% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.68, P/B of 0.94, and consistent earnings beats in recent quarters. Revenue grew from $17.77T in 2022 to $21.23T in 2025, with net income rising to $5.83T. Operating cash flow improved significantly to $4.23T in 2025, while analyst consensus shows 33% buy ratings amid positive momentum coverage.
KB presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term consolidation. Key risks include market volatility and execution challenges in non-banking expansion. The stock's current price near support levels and strong institutional interest support a cautiously optimistic outlook for patient investors.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
